Cargando…
Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study)
BACKGROUND: Women with highly penetrant BRCA mutations have a 55–60% lifetime risk for breast cancer and a 16–59% lifetime risk for ovarian cancer. However, penetrance differs interindividually, indicating that environmental and behavioral factors may modify this risk. These include lifestyle factor...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165708/ https://www.ncbi.nlm.nih.gov/pubmed/28031860 http://dx.doi.org/10.1186/s40814-016-0114-7 |
_version_ | 1782482877002285056 |
---|---|
author | Kiechle, Marion Engel, Christoph Berling, Anika Hebestreit, Katrin Bischoff, Stephan Dukatz, Ricarda Gerber, Wolf-Dieter Siniatchkin, Michael Pfeifer, Katharina Grill, Sabine Yahiaoui-Doktor, Maryam Kirsch, Ellen Niederberger, Uwe Marter, Nicole Enders, Ute Löffler, Markus Meindl, Alfons Rhiem, Kerstin Schmutzler, Rita Erickson, Nicole Halle, Martin |
author_facet | Kiechle, Marion Engel, Christoph Berling, Anika Hebestreit, Katrin Bischoff, Stephan Dukatz, Ricarda Gerber, Wolf-Dieter Siniatchkin, Michael Pfeifer, Katharina Grill, Sabine Yahiaoui-Doktor, Maryam Kirsch, Ellen Niederberger, Uwe Marter, Nicole Enders, Ute Löffler, Markus Meindl, Alfons Rhiem, Kerstin Schmutzler, Rita Erickson, Nicole Halle, Martin |
author_sort | Kiechle, Marion |
collection | PubMed |
description | BACKGROUND: Women with highly penetrant BRCA mutations have a 55–60% lifetime risk for breast cancer and a 16–59% lifetime risk for ovarian cancer. However, penetrance differs interindividually, indicating that environmental and behavioral factors may modify this risk. These include lifestyle factors such as physical activity status, dietary habits, and body weight. The modification of penetrance by changing lifestyle factors has not thus far been investigated in a randomized trial in BRCA mutation carriers. METHODS: Therefore, we intend to enroll 60 BRCA1/2 mutation carriers in a pilot feasibility study (Lifestyle Intervention Study in Women with Hereditary Breast and Ovarian Cancer (LIBRE) pilot). This multi-center, prospective, controlled trial aims to randomize (1:1) participants into a (1) multi-factorial lifestyle intervention group (IG) versus (2) the control group with usual care (CG). The primary endpoint is feasibility and acceptance of a structured interdisciplinary lifestyle intervention program over 12 months (at least 70% of the patients to complete the 1-year intervention). Furthermore, the effects on physical fitness, BMI, quality of life, and stress coping capacity will be investigated. During the first 3 months, women in the IG will receive structured, individualized and mainly supervised endurance training of ≥18 MET*h/week (MET = metabolic equivalent task) and personal nutritional counseling based on the Mediterranean diet. During the subsequent 9 months, the IG will receive monthly group training sessions and regular telephone contacts for motivation, whereas the CG will only receive usual care (one general counseling on healthy nutrition and benefits of regular physical activity on health status). At randomization and subsequent time points (3, 6, 12 months), cardiopulmonary fitness will be assessed by spiroergometry and nutritional and psychological status by validated questionnaires. DISCUSSION: This pilot study will investigate the optimal strategy to improve physical fitness, nutritional habits, and psychological factors in women at high risk for developing breast or ovarian cancer. The results of this pilot feasibility study will be the basis for a larger prospective randomized trial including clinical events (LIBRE). TRIAL REGISTRATION: ClinicalTrials.gov, NCT02087592 |
format | Online Article Text |
id | pubmed-5165708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-51657082016-12-28 Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study) Kiechle, Marion Engel, Christoph Berling, Anika Hebestreit, Katrin Bischoff, Stephan Dukatz, Ricarda Gerber, Wolf-Dieter Siniatchkin, Michael Pfeifer, Katharina Grill, Sabine Yahiaoui-Doktor, Maryam Kirsch, Ellen Niederberger, Uwe Marter, Nicole Enders, Ute Löffler, Markus Meindl, Alfons Rhiem, Kerstin Schmutzler, Rita Erickson, Nicole Halle, Martin Pilot Feasibility Stud Study Protocol BACKGROUND: Women with highly penetrant BRCA mutations have a 55–60% lifetime risk for breast cancer and a 16–59% lifetime risk for ovarian cancer. However, penetrance differs interindividually, indicating that environmental and behavioral factors may modify this risk. These include lifestyle factors such as physical activity status, dietary habits, and body weight. The modification of penetrance by changing lifestyle factors has not thus far been investigated in a randomized trial in BRCA mutation carriers. METHODS: Therefore, we intend to enroll 60 BRCA1/2 mutation carriers in a pilot feasibility study (Lifestyle Intervention Study in Women with Hereditary Breast and Ovarian Cancer (LIBRE) pilot). This multi-center, prospective, controlled trial aims to randomize (1:1) participants into a (1) multi-factorial lifestyle intervention group (IG) versus (2) the control group with usual care (CG). The primary endpoint is feasibility and acceptance of a structured interdisciplinary lifestyle intervention program over 12 months (at least 70% of the patients to complete the 1-year intervention). Furthermore, the effects on physical fitness, BMI, quality of life, and stress coping capacity will be investigated. During the first 3 months, women in the IG will receive structured, individualized and mainly supervised endurance training of ≥18 MET*h/week (MET = metabolic equivalent task) and personal nutritional counseling based on the Mediterranean diet. During the subsequent 9 months, the IG will receive monthly group training sessions and regular telephone contacts for motivation, whereas the CG will only receive usual care (one general counseling on healthy nutrition and benefits of regular physical activity on health status). At randomization and subsequent time points (3, 6, 12 months), cardiopulmonary fitness will be assessed by spiroergometry and nutritional and psychological status by validated questionnaires. DISCUSSION: This pilot study will investigate the optimal strategy to improve physical fitness, nutritional habits, and psychological factors in women at high risk for developing breast or ovarian cancer. The results of this pilot feasibility study will be the basis for a larger prospective randomized trial including clinical events (LIBRE). TRIAL REGISTRATION: ClinicalTrials.gov, NCT02087592 BioMed Central 2016-12-19 /pmc/articles/PMC5165708/ /pubmed/28031860 http://dx.doi.org/10.1186/s40814-016-0114-7 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Kiechle, Marion Engel, Christoph Berling, Anika Hebestreit, Katrin Bischoff, Stephan Dukatz, Ricarda Gerber, Wolf-Dieter Siniatchkin, Michael Pfeifer, Katharina Grill, Sabine Yahiaoui-Doktor, Maryam Kirsch, Ellen Niederberger, Uwe Marter, Nicole Enders, Ute Löffler, Markus Meindl, Alfons Rhiem, Kerstin Schmutzler, Rita Erickson, Nicole Halle, Martin Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study) |
title | Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study) |
title_full | Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study) |
title_fullStr | Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study) |
title_full_unstemmed | Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study) |
title_short | Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (LIBRE-1 study) |
title_sort | lifestyle intervention in brca1/2 mutation carriers: study protocol for a prospective, randomized, controlled clinical feasibility trial (libre-1 study) |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165708/ https://www.ncbi.nlm.nih.gov/pubmed/28031860 http://dx.doi.org/10.1186/s40814-016-0114-7 |
work_keys_str_mv | AT kiechlemarion lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT engelchristoph lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT berlinganika lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT hebestreitkatrin lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT bischoffstephan lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT dukatzricarda lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT gerberwolfdieter lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT siniatchkinmichael lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT pfeiferkatharina lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT grillsabine lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT yahiaouidoktormaryam lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT kirschellen lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT niederbergeruwe lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT marternicole lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT endersute lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT lofflermarkus lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT meindlalfons lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT rhiemkerstin lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT schmutzlerrita lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT ericksonnicole lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study AT hallemartin lifestyleinterventioninbrca12mutationcarriersstudyprotocolforaprospectiverandomizedcontrolledclinicalfeasibilitytriallibre1study |